Evidence map›Paper›PMID 31772574›Full record

ArticleInternational journal of endocrinology2019

Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats.

Yohei Asada, Takeshi Takayanagi, Tsukasa Kawakami, Eisuke Tomatsu, Atsushi Masuda, Yasumasa Yoshino, Sahoko Sekiguchi-Ueda, Megumi Shibata, Tomihiko Ide, Hajime Niimi and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Yohei AsadaDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Takeshi TakayanagiDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Tsukasa KawakamiDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Eisuke TomatsuDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Atsushi MasudaDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Yasumasa YoshinoDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Sahoko Sekiguchi-UedaDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Megumi ShibataDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Tomihiko IdeJoint Research Support Promotion Facility, Center for Research Promotion and Support, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Hajime NiimiDepartment of Anatomy, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Eishin YaoitaDepartment of Structural Pathology, Institute of Nephrology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 950-2102, Japan.
Yusuke SeinoDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Yoshihisa SugimuraDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Atsushi SuzukiDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, Japan.ORCID https://orcid.org/0000-0003-0807-199X
Fujita Health University · JPNiigata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis patients with chronic kidney disease (CKD) are becoming common in our superaging society. Renal dysfunction causes phosphorus accumulation in the circulating plasma and leads to the development of CKD-mineral bone disorder (MBD). We have previously reported that type III Pi transporter-overexpressing transgenic (Pit-1 TG) rats manifest phosphate (Pi)-dependent podocyte injury. In the present study, we explored the effect of risedronate on Pi-induced podocyte injury

Identifiers

PMID31772574
PMCPMC6854176
OpenAlexW2981716576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.